Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4096591
Max Phase: Preclinical
Molecular Formula: C15H14FN5O4
Molecular Weight: 347.31
Molecule Type: Small molecule
Associated Items:
ID: ALA4096591
Max Phase: Preclinical
Molecular Formula: C15H14FN5O4
Molecular Weight: 347.31
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=[N+]([O-])c1c(NCCCO)cc(Nc2ccc(F)cc2)c2nonc12
Standard InChI: InChI=1S/C15H14FN5O4/c16-9-2-4-10(5-3-9)18-11-8-12(17-6-1-7-22)15(21(23)24)14-13(11)19-25-20-14/h2-5,8,17-18,22H,1,6-7H2
Standard InChI Key: FHHZOEZSHUCDJI-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 347.31 | Molecular Weight (Monoisotopic): 347.1030 | AlogP: 2.81 | #Rotatable Bonds: 7 |
Polar Surface Area: 126.35 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 13.70 | CX Basic pKa: 0.96 | CX LogP: 2.34 | CX LogD: 2.34 |
Aromatic Rings: 3 | Heavy Atoms: 25 | QED Weighted: 0.34 | Np Likeness Score: -1.59 |
1. Yasui T, Yamamoto T, Sakai N, Asano K, Takai T, Yoshitomi Y, Davis M, Takagi T, Sakamoto K, Sogabe S, Kamada Y, Lane W, Snell G, Iwata M, Goto M, Inooka H, Sakamoto JI, Nakada Y, Imaeda Y.. (2017) Discovery of a novel B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor by utilizing structure-based drug design., 25 (17): [PMID:28760529] [10.1016/j.bmc.2017.07.037] |
Source(1):